161 related articles for article (PubMed ID: 21438849)
1. Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Bruce RD; Moody DE; Fang WB; Chodkowski D; Andrews L; Friedland GH
Am J Drug Alcohol Abuse; 2011 Jul; 37(4):224-8. PubMed ID: 21438849
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Bruce RD; Altice FL; Moody DE; Lin SN; Fang WB; Sabo JP; Wruck JM; Piliero PJ; Conner C; Andrews L; Friedland GH
Drug Alcohol Depend; 2009 Dec; 105(3):234-9. PubMed ID: 19726139
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.
Bruce RD; Altice FL; Moody DE; Morse GD; Andrews L; Lin SN; Fang WB; Ma Q; Friedland GH
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):511-4. PubMed ID: 20672450
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.
Douglas Bruce R; Moody DE; Chodkowski D; Andrews L; Fang WB; Morrison J; Parsons TL; Friedland GH
Am J Drug Alcohol Abuse; 2013 Mar; 39(2):80-5. PubMed ID: 23421567
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment.
Bruce RD; Winkle P; Custodio JM; Wei LX; Rhee MS; Kearney BP; Ramanathan S; Friedland GH
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):480-4. PubMed ID: 23599011
[TBL] [Abstract][Full Text] [Related]
6. Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Moore K; Magee M; Sevinsky H; Chang M; Lubin S; Myers E; Ackerman P; Llamoso C
Br J Clin Pharmacol; 2019 Aug; 85(8):1771-1780. PubMed ID: 30980734
[TBL] [Abstract][Full Text] [Related]
7. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
Sekar V; Tomaka F; Lefebvre E; De Pauw M; Vangeneugden T; van den Brink W; Hoetelmans R
J Clin Pharmacol; 2011 Feb; 51(2):271-8. PubMed ID: 20421512
[No Abstract] [Full Text] [Related]
9. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers.
la Porte CJ; Sabo JP; Elgadi M; Cameron DW
Antimicrob Agents Chemother; 2009 Jan; 53(1):162-73. PubMed ID: 19015362
[TBL] [Abstract][Full Text] [Related]
10. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir.
Hanley WD; Wenning LA; Moreau A; Kost JT; Mangin E; Shamp T; Stone JA; Gottesdiener KM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2009 Jul; 53(7):2752-5. PubMed ID: 19398643
[TBL] [Abstract][Full Text] [Related]
11. Editor's Highlight: Neurorespiratory Effects of Buprenorphine and Ethanol in Combination: A Mechanistic Study of Drug-Drug Interactions in the Rat.
Cohier C; Chevillard L; Salle S; Risède P; Roussel O; Mégarbane B
Toxicol Sci; 2017 Feb; 155(2):389-399. PubMed ID: 27803387
[TBL] [Abstract][Full Text] [Related]
12. Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.
Sabo JP; Cong XJ; Kraft MF; Wallace L; Castles MA; Mauss S; MacGregor TR
Eur J Clin Pharmacol; 2011 Mar; 67(3):277-81. PubMed ID: 20963404
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.
MacGregor TR; Sabo JP; Norris SH; Johnson P; Galitz L; McCallister S
HIV Clin Trials; 2004; 5(6):371-82. PubMed ID: 15682350
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine and nor-buprenorphine levels in head hair samples from former heroin users under Suboxone® treatment.
Belivanis S; Tzatzarakis MN; Vakonaki E; Kovatsi L; Mantsi M; Alegakis A; Kavvalakis MP; Vynias D; Tsatsakis AM
Drug Test Anal; 2014 Jun; 6 Suppl 1():93-100. PubMed ID: 24817054
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.
Zhang H; Bastian JR; Zhao W; Chen H; Shaik IH; Chaphekar N; Caritis SN; Venkataramanan R
Ther Drug Monit; 2020 Apr; 42(2):264-270. PubMed ID: 31929398
[TBL] [Abstract][Full Text] [Related]
16. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
Li F; Wang L; Guo GL; Ma X
Drug Metab Dispos; 2010 May; 38(5):871-8. PubMed ID: 20103582
[TBL] [Abstract][Full Text] [Related]
17. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
Vergara-Rodriguez P; Tozzi MJ; Botsko M; Nandi V; Altice F; Egan JE; O'Connor PG; Sullivan LE; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S62-7. PubMed ID: 21317596
[TBL] [Abstract][Full Text] [Related]
18. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.
Gruber VA; Rainey PM; Moody DE; Morse GD; Ma Q; Prathikanti S; Pade PA; Alvanzo AA; McCance-Katz EF
Clin Infect Dis; 2012 Feb; 54(3):414-23. PubMed ID: 22100576
[TBL] [Abstract][Full Text] [Related]
19. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.
McCance-Katz EF; Moody DE; Smith PF; Morse GD; Friedland G; Pade P; Baker J; Alvanzo A; Jatlow P; Rainey PM
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S235-46. PubMed ID: 17109310
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.
la Porte CJ; Sabo JP; Béïque L; Cameron DW
Antimicrob Agents Chemother; 2009 Nov; 53(11):4840-4. PubMed ID: 19721063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
